CALML6 as a potential diagnostic marker for thyroid cancer promotes thyroid cancer cell proliferation via modulating the immune microenvironment.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[PURPOSE] CALML6 is an inflammation-related gene, and its expression may be associated with cancer.
APA
Cheng C, Shi W, et al. (2025). CALML6 as a potential diagnostic marker for thyroid cancer promotes thyroid cancer cell proliferation via modulating the immune microenvironment.. Gene, 936, 149115. https://doi.org/10.1016/j.gene.2024.149115
MLA
Cheng C, et al.. "CALML6 as a potential diagnostic marker for thyroid cancer promotes thyroid cancer cell proliferation via modulating the immune microenvironment.." Gene, vol. 936, 2025, pp. 149115.
PMID
39571661 ↗
Abstract 한글 요약
[PURPOSE] CALML6 is an inflammation-related gene, and its expression may be associated with cancer. Here we evaluated the role of CALML6 expression in papillary thyroid carcinoma (PTC).
[METHODS] We utilized databases such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx) and UALCAN to evaluate the relationship between CALML6 expression and clinicopathological features in thyroid cancer. Immunohistochemical assays were used to observe CALML6 expression in thyroid cancer tissues. The role of CALML6 in PTC cells was investigated using RNA interference.
[RESULTS] We found CALML6 expression was lower than normal and associated with extrathyroidal extension, lymph node metastasis, pathological T stage, tall cell PTC and the expressions of immune checkpoint genes CD274 and PDCD1LG2 in THCA. Additionally, Immunohistochemical staining showed that CALML6 expression was significantly upregulated in thyroid cancer tissues. RNAi analysis showed that CALML6 knockdown significantly reduced cell growth and blocked the cell cycle of PTC cells.
[CONCLUSIONS] Our results suggest that CALML6 may be a novel diagnostic marker for PTC that is closely associated with the invasive and tall cell subtypes, and it may be a potential target for immunotherapy.
[METHODS] We utilized databases such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx) and UALCAN to evaluate the relationship between CALML6 expression and clinicopathological features in thyroid cancer. Immunohistochemical assays were used to observe CALML6 expression in thyroid cancer tissues. The role of CALML6 in PTC cells was investigated using RNA interference.
[RESULTS] We found CALML6 expression was lower than normal and associated with extrathyroidal extension, lymph node metastasis, pathological T stage, tall cell PTC and the expressions of immune checkpoint genes CD274 and PDCD1LG2 in THCA. Additionally, Immunohistochemical staining showed that CALML6 expression was significantly upregulated in thyroid cancer tissues. RNAi analysis showed that CALML6 knockdown significantly reduced cell growth and blocked the cell cycle of PTC cells.
[CONCLUSIONS] Our results suggest that CALML6 may be a novel diagnostic marker for PTC that is closely associated with the invasive and tall cell subtypes, and it may be a potential target for immunotherapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Itaconate as a Potent Regulator of Neutrophil Responses in Host Defence and Inflammation.
- Prognostic Utility of a Deep Learning Radiomics Nomogram Integrating Ultrasound and Multi-Sequence MRI in Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy.
- Analysis of the Clinical Value of hsa_circ_0001955 in Papillary Thyroid Cancer Treated with 131 Iodine.
- Integration of a novel anti-PD-1 antibody with chimeric antigen receptor-T engineered to express interleukin-7 enhances targeting efficacy against lung cancer.
- Overall survival according to time-of-day of combined immuno-chemotherapy for advanced gastric cancer: a propensity score-matched analysis.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.